A new clinical trial from Mass General Brigham found that a drug approved for other indications helped early morning shift workers with shift work disorder stay more alert.
About 45,000 prescriptions were written for sunosi (solriamfetol) in Q2, according to Axsome Therapeutics Inc, with 4,200 of those being for new patients.
One poster will feature results from the SHARP study, a trial of Sunosi in 59 patients with excessive daytime sleepiness associated with OSA and impaired cognitive function.
Read More
In its Q2 business highlights, Axsome Therapeutics provided updates on a new potential indication for solriamfetol for shift work disorder, announced progress for its narcolepsy drug candidate, and revealed positive results from the relaunch of Sunosi.
Read More
A patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read More
The presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
Read More
Axsome Therapeutics will present data on Sunosi, including results from the SHARP study, at the American Society of Clinical Psychopharmacology Annual Meeting, being held May 30 to June 3.
Read More
Axsome Therapeutics reported first-quarter corporate updates, noting a growing patient base for Sunosi and progress for its narcolepsy drug candidate AXS-12.
Read More
Solriamfetol is being trialed in 59 patients with excessive daytime sleepiness associated with obstructive sleep apnea and impaired cognitive function.
Read More
Axsome Therapeutics discusses what’s next for Sunosi, used to reduce excessive daytime sleepiness in adults with narcolepsy or sleep apnea, and AXS-12, a narcolepsy drug candidate in clinical trials.
Read More
The license agreement will expand the availability of Sunosi, a medicine used to reduce excessive daytime sleepiness in adults with narcolepsy or OSA, across Europe and MENA.
Read More
SHARP was a randomized, double-blind, placebo-controlled, crossover, multicenter, trial in 59 patients with excessive daytime sleepiness associated with OSA, and impaired cognitive function.
Read More
New research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read More
‘The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.’
Read MoreThirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read More
Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor for the treatment of persistent daytime sleepiness in adults.
Read MoreSolriamfetol significantly improved driving performance for patients with narcolepsy and daytime sleepiness due to obstructive sleep apnea, according to a pair of on-road driving studies sponsored by the drugmaker.
Read More